Profusa (PFSA) Gains from Investment Securities (2022 - 2026)
Profusa's (PFSA) quarterly Gains from Investment Securities came in at -$258000.0 in Q1 2026, down 262.95% year-on-year from $158335.0 in Q1 2025, and down 124.09% quarter-over-quarter from $1.1 million in Q4 2025.
Profusa (PFSA) Gains from Investment Securities (2022 - 2026) Analysis & Trends
Profusa's Gains from Investment Securities history runs 5 years deep, the most recent figure standing at -$258000.0 for Q1 2026.
- On a quarterly basis, Gains from Investment Securities fell 262.95% year-over-year to -$258000.0 in Q1 2026; TTM through Mar 2026 was $5.8 million, a 2130.08% increase from a year earlier, with the FY2025 full-year figure at $187000.0, down 65.34% from the prior year.
- Gains from Investment Securities retreated to -$258000.0 in Q1 2026 per PFSA's latest filing, from $1.1 million in the prior quarter.
- Across five years, Gains from Investment Securities topped out at $5.9 million in Q2 2025 and bottomed at -$3.9 million in Q1 2022.
- The 5-year median for Gains from Investment Securities is -$41991.0 (2022), against an average of $44813.0.
- Across the five-year window, Gains from Investment Securities tumbled 932.37% in 2023 and soared 1900.0% in 2025, its largest moves.
- Year by year, Gains from Investment Securities stood at -$111338.0 in 2022, then tumbled by 359.02% to -$511069.0 in 2023, then soared by 122.02% to $112531.0 in 2024, then jumped by 851.74% to $1.1 million in 2025, then plunged by 124.09% to -$258000.0 in 2026.
- Per Business Quant, the three latest PFSA Gains from Investment Securities figures stand at -$258000.0 (Q1 2026), $1.1 million (Q4 2025), and -$884000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn |
| 10 | Profusa | 77,314.98 | -297,685.02 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -258,000.00 |
| Mar 31, 2026 | -258,000.00 |
| Dec 31, 2025 | 1.07 Mn |
| Dec 31, 2025 | 1.07 Mn |
| Sep 30, 2025 | -884,000.00 |
| Sep 30, 2025 | -884,000.00 |
| Jun 30, 2025 | 5.92 Mn |
| Jun 30, 2025 | 5.92 Mn |
| Mar 31, 2025 | 158,335.00 |
| Mar 31, 2025 | 158,335.00 |
| Dec 31, 2024 | 112,531.00 |
| Dec 31, 2024 | 112,531.00 |
| Sep 30, 2024 | -304,575.00 |
| Sep 30, 2024 | -304,575.00 |
| Jun 30, 2024 | 295,872.00 |
| Jun 30, 2024 | 295,872.00 |
| Mar 31, 2024 | 213,077.00 |
| Mar 31, 2024 | 213,077.00 |
| Dec 31, 2023 | -511,069.00 |
| Dec 31, 2023 | -511,069.00 |